Literature DB >> 19189306

Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.

Ganesh S Palapattu1, Chengyu Wu, Christopher R Silvers, Heather B Martin, Karin Williams, Linda Salamone, Timothy Bushnell, Li-Shan Huang, Qi Yang, Jiaoti Huang.   

Abstract

BACKGROUND: Hormonal therapy is effective for advanced prostate cancer (PC) but the disease often recurs and becomes hormone-refractory. It is hypothesized that a subpopulation of cancer cells, that is, cancer stem cells (CSCs), survives hormonal therapy and leads to tumor recurrence. CD44 expression was shown to identify tumor cells with CSC features. PC contains secretory type epithelial cells and a minor population of neuroendocrine cells. Neuroendocrine cells do not express androgen receptor and are quiescent, features associated with CSCs. The purpose of the study was to determine the expression of CD44 in human PC and its relationship to neuroendocrine tumor cells.
METHODS: Immunohistochemistry and immunofluorescence were performed to study CD44 expression in PC cell lines, single cells from fresh PC tissue and archival tissue sections of PC. We then determined if CD44+ cells represent neuroendocrine tumor cells.
RESULTS: In human PC cell lines, expression of CD44 is associated with cells of NE phenotype. In human PC tissues, NE tumor cells are virtually all positive for CD44 and CD44+ cells, excluding lymphocytes, are all NE tumor cells.
CONCLUSIONS: Selective expression of the stem cell-associated marker CD44 in NE tumor cells of PC, in combination with their other known features, further supports the significance of such cells in therapy resistance and tumor recurrence. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189306     DOI: 10.1002/pros.20928

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  65 in total

Review 1.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

2.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.

Authors:  Hsiang-Yu Lin; Yi-Chiu Kuo; Yu-I Weng; I-Lu Lai; Tim H-M Huang; Shuan-Pei Lin; Dau-Ming Niu; Ching-Shih Chen
Journal:  Prostate       Date:  2012-04-26       Impact factor: 4.104

3.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Neuroendocrine prostate carcinoma cells originate from the p63-expressing basal cells but not the pre-existing adenocarcinoma cells in mice.

Authors:  Dong-Kee Lee; Yonghong Liu; Lan Liao; Wenliang Li; David Danielpour; Jianming Xu
Journal:  Cell Res       Date:  2019-02-18       Impact factor: 25.617

Review 5.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

6.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Authors:  Hongbing Chen; Yin Sun; Chengyu Wu; Clara E Magyar; Xinmin Li; Liang Cheng; Jorge L Yao; Steven Shen; Adeboye O Osunkoya; Chaozhao Liang; Jiaoti Huang
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

7.  Stemness-Related Markers in Cancer.

Authors:  Wenxiu Zhao; Yvonne Li; Xun Zhang
Journal:  Cancer Transl Med       Date:  2017-06-08

8.  The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade.

Authors:  Xiao-Feng Le; Omar Merchant; Robert C Bast; George A Calin
Journal:  Cancer Microenviron       Date:  2010-02-23

9.  The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.

Authors:  Su-Ni Tang; Chandan Singh; Dara Nall; Daniel Meeker; Sharmila Shankar; Rakesh K Srivastava
Journal:  J Mol Signal       Date:  2010-08-18

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.